Literature DB >> 10910916

Interleukin-15 redirects the outcome of a tolerizing T-cell stimulus from apoptosis to anergy.

H Dooms1, T Van Belle, M Desmedt, P Rottiers, J Grooten.   

Abstract

Clonal deletion and anergy are 2 mechanisms used by the immune system to establish peripheral tolerance. In vitro, these mechanisms are induced in T lymphocytes by triggering the T-cell receptor (signal 1) in the absence of costimulation (signal 2). T-cell clones have been shown either to become anergic or to die in response to signal 1 alone; yet the factors that govern this choice remain unknown. This study evaluated the influence of the cytokines interleukin (IL)-2 and IL-15 on the response of the Th1 clone hemagglutinin (T-HA) to signal 1, delivered by stimulation with immobilized anti-CD3 monoclonal antibody (mAb). The response induced by immobilized anti-CD3 mAb was dependent on the cytokine milieu; in the presence of IL-2, T-HA cells were subject to apoptosis, whereas in the presence of IL-15 the cells remained viable but showed proliferative unresponsiveness. After release from the anti-CD3 stimulus, the IL-15-rescued T-HA cells regained responsiveness to IL-2 and IL-15 growth factor activity. However, they were unable to proliferate when stimulated with their cognate antigen presented by professional antigen-presenting cells (signal 1 plus 2) and thus had acquired an anergic phenotype. These data assign a novel function to the previously reported antiapoptotic activity of IL-15, namely, the capacity to redirect the T-cell response to partial stimulation from clonal deletion to anergy. Furthermore, they emphasize that the cytokine environment can critically influence the outcome of a tolerizing stimulus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910916

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Induction of IL-15 by TCR/CD3 aggregation depends on IFN-gamma and protects against apoptosis of immature thymocytes in vivo.

Authors:  P Matthys; H Dooms; P Rottiers; T Mitera; L Overgergh; G Leclercq; A Billiau; J Grooten
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 3.  Review article: molecular signals and genetic reprogramming in peripheral T-cell differentiation.

Authors:  A Noble
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

4.  Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.

Authors:  M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.

Authors:  Jesse Rowley; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

6.  IL-15 augments TCR-induced CD4+ T cell expansion in vitro by inhibiting the suppressive function of CD25 High CD4+ T cells.

Authors:  Tom L Van Belle; Hans Dooms; Tom Boonefaes; Xiao-Qing Wei; Georges Leclercq; Johan Grooten
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

7.  Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure.

Authors:  Marianna Di Scala; Irene Gil-Fariña; Cristina Olagüe; Africa Vales; Luciano Sobrevals; Puri Fortes; David Corbacho; Gloria González-Aseguinolaza
Journal:  Oncotarget       Date:  2016-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.